FDG-PET imaging in duodenal cancer

Annals of Nuclear Medicine

Volumn 18, Issue 4, 2004, Pages 351-353

  Watanabe, Naoto ^a   Hayashi, Shinichi ^a   Kato, Hiroshi ^a   Shimizu, Masashi ^a   Kamisaki, Yuichi ^a   Noguchi, Kyo ^a   Kishida, Mika ^a   Matsunari, Ichiro ^b   Hisada, Kinichi ^b   Seto, Hikaru ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Med and Pharmaceutical Res Found

Author keywords

Duodenal cancer; FDG PET; Multiple metastases; Tumor imaging

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18;

ADENOCARCINOMA; ADRENAL GLAND; AGED; ARTICLE; BRAIN METASTASIS; CASE REPORT; CLAVICLE; COMPUTER ASSISTED TOMOGRAPHY; DUODENUM BIOPSY; DUODENUM CANCER; FEMALE; FIBERSCOPE ENDOSCOPY; HUMAN; LYMPH NODE METASTASIS; MEDIASTINUM; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 4143080222     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02984475     Document Type: Article

References (14)

1. Cortese AF, Cornell GN. Carcinoma of the duodenum. Cancer 1972; 29: 1010-1015.
2. Spira IA, Ghazi A, Wolff WI. Primary adenocarcinoma of the duodenum. Cancer 1977; 39: 1721-1726.
3. Kubota K, Matsuzawa T, Fujiwara T, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990; 31: 1927-1932.
4. Okada J, Yoshikawa K, Imazeki K, et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med 1991; 32: 686-691.
5. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991; 32: 623-648.
6. 18F]fluoro-D-glucose in liver metastases from colon carcinoma. J Nucl Med 1982; 23: 1133-1137.
7. 18F-FDG positron emission tomography in gastric and oesophageal carcinoma. Br J Radiol 1999; 72: 525-529
8. Arai T, Murata T, Sawabe M, et al. Primary adenocarcinoma of the duodenum in the elderly: clinicopathological and immunohistochemical study of 17 cases. Pathol Int 1999; 49: 23-29.
9. De Potter T, Flamen P, Van Cutsem E, et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med 2002; 29: 525-529.
10. Stahl A, Otto K, Weber WA, et al. Correlation of FDG uptake in gastric carcinomas with endoscopic and histopathological findings. J Nucl Med 2001; 42: 78P-79P.
11. Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer 2001; 92: 634-641.
12. Higashi T, Tamaki N, Honda T, et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med 1997; 38: 1337-1344.
13. Jeong HJ, Chung JK, Kim YK, et al. Usefulness of whole-body (18)F-FDG PET in patients with suspected metastatic brain tumors. J Nucl Med 2002; 43: 1432-1437.
14. Rohren EM, Provenzale JM, Barboriak DP, Coleman RE. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology 2003; 226: 181-187.